Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study
Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/20/12511 |
| _version_ | 1797472688457908224 |
|---|---|
| author | Susann Stephan-Falkenau Anna Streubel Thomas Mairinger Jens Kollmeier Daniel Misch Sebastian Thiel Torsten Bauer Joachim Pfannschmidt Manuel Hollmann Michael Wessolly Torsten Gerriet Blum |
| author_facet | Susann Stephan-Falkenau Anna Streubel Thomas Mairinger Jens Kollmeier Daniel Misch Sebastian Thiel Torsten Bauer Joachim Pfannschmidt Manuel Hollmann Michael Wessolly Torsten Gerriet Blum |
| author_sort | Susann Stephan-Falkenau |
| collection | DOAJ |
| description | Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC (stages I–IIIA). Furthermore, patients with elevated programmed death-ligand 1 (PD-L1) expression appear to respond favorably to adjuvant immunotherapy. To determine the frequency of genomic alterations and PD-L1 status in early-stage NSCLC, we retrospectively analyzed data from 2066 unselected, single-center patients with NSCLC diagnosed using next-generation sequencing and immunohistochemistry. Nine-hundred and sixty-two patients (46.9%) presented with early-stage NSCLC. Of these, 37.0% had genomic alterations for which targeted therapies have already been approved for advanced NSCLC. The frequencies of driver mutations in the early stages were equivalent to those in advanced stages, i.e., the rates of EGFR mutations in adenocarcinomas were 12.7% (72/567) and 12.0% (78/650) in early and advanced NSCLC, respectively (<i>p</i> = 0778). In addition, 46.3% of early-stage NSCLC cases were PD-L1-positive, with a tumor proportion score (TPS) of ≥1%. With comparable frequencies of driver mutations in early and advanced NSCLC and PD-L1 overexpression in nearly half of patients with early-stage NSCLC, a broad spectrum of biomarkers for adjuvant and neoadjuvant therapies is available, and several are currently being investigated in clinical trials. |
| first_indexed | 2024-03-09T20:05:48Z |
| format | Article |
| id | doaj.art-62bbd80ddde14f58b397297d13af80ae |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T20:05:48Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-62bbd80ddde14f58b397297d13af80ae2023-11-24T00:32:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-10-0123201251110.3390/ijms232012511Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational StudySusann Stephan-Falkenau0Anna Streubel1Thomas Mairinger2Jens Kollmeier3Daniel Misch4Sebastian Thiel5Torsten Bauer6Joachim Pfannschmidt7Manuel Hollmann8Michael Wessolly9Torsten Gerriet Blum10Institute for Tissue Diagnostics, MVZ at Helios Klinikum Emil von Behring, 14165 Berlin, GermanyInstitute for Tissue Diagnostics, MVZ at Helios Klinikum Emil von Behring, 14165 Berlin, GermanyInstitute for Tissue Diagnostics, MVZ at Helios Klinikum Emil von Behring, 14165 Berlin, GermanyDepartment of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyDepartment of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyDepartment of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyDepartment of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyDepartment of Thoracic Surgery, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyInstitute for Tissue Diagnostics, MVZ at Helios Klinikum Emil von Behring, 14165 Berlin, GermanyInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, 14165 Berlin, GermanyPrecision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC (stages I–IIIA). Furthermore, patients with elevated programmed death-ligand 1 (PD-L1) expression appear to respond favorably to adjuvant immunotherapy. To determine the frequency of genomic alterations and PD-L1 status in early-stage NSCLC, we retrospectively analyzed data from 2066 unselected, single-center patients with NSCLC diagnosed using next-generation sequencing and immunohistochemistry. Nine-hundred and sixty-two patients (46.9%) presented with early-stage NSCLC. Of these, 37.0% had genomic alterations for which targeted therapies have already been approved for advanced NSCLC. The frequencies of driver mutations in the early stages were equivalent to those in advanced stages, i.e., the rates of EGFR mutations in adenocarcinomas were 12.7% (72/567) and 12.0% (78/650) in early and advanced NSCLC, respectively (<i>p</i> = 0778). In addition, 46.3% of early-stage NSCLC cases were PD-L1-positive, with a tumor proportion score (TPS) of ≥1%. With comparable frequencies of driver mutations in early and advanced NSCLC and PD-L1 overexpression in nearly half of patients with early-stage NSCLC, a broad spectrum of biomarkers for adjuvant and neoadjuvant therapies is available, and several are currently being investigated in clinical trials.https://www.mdpi.com/1422-0067/23/20/12511lung cancermolecular pathologyprecision oncologybiomarker-driven targeted therapyearly-stage NSCLCEGFR mutation |
| spellingShingle | Susann Stephan-Falkenau Anna Streubel Thomas Mairinger Jens Kollmeier Daniel Misch Sebastian Thiel Torsten Bauer Joachim Pfannschmidt Manuel Hollmann Michael Wessolly Torsten Gerriet Blum Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study International Journal of Molecular Sciences lung cancer molecular pathology precision oncology biomarker-driven targeted therapy early-stage NSCLC EGFR mutation |
| title | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study |
| title_full | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study |
| title_fullStr | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study |
| title_full_unstemmed | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study |
| title_short | Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study |
| title_sort | landscape of genomic alterations and pd l1 expression in early stage non small cell lung cancer nsclc a single center retrospective observational study |
| topic | lung cancer molecular pathology precision oncology biomarker-driven targeted therapy early-stage NSCLC EGFR mutation |
| url | https://www.mdpi.com/1422-0067/23/20/12511 |
| work_keys_str_mv | AT susannstephanfalkenau landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT annastreubel landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT thomasmairinger landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT jenskollmeier landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT danielmisch landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT sebastianthiel landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT torstenbauer landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT joachimpfannschmidt landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT manuelhollmann landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT michaelwessolly landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy AT torstengerrietblum landscapeofgenomicalterationsandpdl1expressioninearlystagenonsmallcelllungcancernsclcasinglecenterretrospectiveobservationalstudy |